ArticleThe Canadian journal of cardiology2006
Trends in five-year survival of patients discharged after acute myocardial infarction.
Article in The Canadian journal of cardiology, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- Lifestyle Interventions and Carotid Plaque Burden: A Comparative Analysis of Two Lifestyle Intervention Programs in Patients with Coronary Artery Disease.The Permanente journal · 2019Trial
- Economic evaluation of high-dose (80 mg/day) atorvastatin treatment compared with standard-dose (20 mg/day to 40 mg/day) simvastatin treatment in Canada based on the Incremental Decrease in End-Points Through Aggressive Lipid-Lowering (IDEAL) trial.The Canadian journal of cardiology · 2009Trial
- Comparison of all-cause and cause-specific mortality after myocardial infarction - a Hungarian registry study.American heart journal plus : cardiology research and practice · 2025Article
- Unravelling the role of macrophages in cardiovascular inflammation through imaging: a state-of-the-art review.European heart journal. Cardiovascular Imaging · 2022Review
- Hyaluronan and elastin-like protein (HELP) gels significantly improve microsphere retention in the myocardium.Biomaterials science · 2022Article
- Antioxidant Effects of Statins by Modulating Nrf2 and Nrf2/HO-1 Signaling in Different Diseases.Journal of clinical medicine · 2022Review
- Characteristics and Outcomes of Early Recurrent Myocardial Infarction After Acute Myocardial Infarction.Journal of the American Heart Association · 2021Article
- Higher Long-Term Mortality in Patients with Non-ST-Elevation Myocardial Infarction than ST-Elevation Myocardial Infarction after Discharge.Yonsei medical journal · 2021Article
- Mortality in older adults following a fragility fracture: real-world retrospective matched-cohort study in Ontario.BMC musculoskeletal disorders · 2021Article
- Natural Biomaterials for Cardiac Tissue Engineering: A Highly Biocompatible Solution.Frontiers in cardiovascular medicine · 2020Review
- Management of established coronary artery disease in aircrew with previous myocardial infarction or revascularisation.Heart (British Cardiac Society) · 2019Review
- Risk of a first-ever acute myocardial infarction and all-cause mortality with sulphonylurea treatment: A population-based cohort study.Diabetes, obesity & metabolism · 2018Article
- Nrf2 at the heart of oxidative stress and cardiac protection.Physiological genomics · 2018Review
- Feasibility of detecting myocardial infarction in the sheep fetus using late gadolinium enhancement CMR imaging.Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance · 2017Article
- Prophylactic orthosteric inhibition of leukocyte integrin CD11b/CD18 prevents long-term fibrotic kidney failure in cynomolgus monkeys.Nature communications · 2017Article
- Article
- Article
- The changing epidemiology of myocardial infarction in Olmsted County, Minnesota, 1995-2012.The American journal of medicine · 2015Article
- Aspirin for Primary Prevention of Cardiovascular Disease and Cancer. A Benefit and Harm Analysis.PloS one · 2015Article
- Marital status shows a strong protective effect on long-term mortality among first acute myocardial infarction-survivors with diagnosed hyperlipidemia--findings from the MONICA/KORA myocardial infarction registry.BMC public health · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIt has previously been shown that the increased use of therapeutic intervention may not reduce patient fatality if there is a simultaneous increase in case severity. The present study was designed to extend the relationship between case severity and therapeutic interventions to long-term survival in the same study population.
objectiveTo compare five-year survival of patients discharged after acute myocardial infarction from 1984 to 1988 and from 1989 to 1993, and to evaluate possible reasons for survival differences.
methodsThe present study was population-based. Survival time was determined by record linkage into the Canadian Mortality Database. Association of five-year survival with patient characteristics, in-hospital treatment and discharge medications was assessed by logistical regression analysis. Case severity was calculated as the probability of death within five years, given the patient profile and excluding any interventions.
resultsBetween the two study periods, most patient characteristics and treatment intensity changed, but case severity for the study population remained constant. Five-year survival improved from 74.8% to 79.2% (P(chi2)=0.001). The improvement was adequately described by the combination of changes in patient profile and treatment without residual period effect (P(goodness-of-fit)=0.752). The treatments significantly associated with five-year survival were coronary artery bypass graft surgery (OR 2.74; 95% CI 1.86 to 4.05), percutaneous coronary intervention (OR 2.63; 95% CI 1.67 to 4.14) and thrombolysis (OR 1.98; 95% CI 1.50 to 2.62) during admission, as well as acetylsalicylic acid (OR 1.39; 95% CI 1.15 to 1.68) or beta-blocker (OR 1.60; 95% CI 1.34 to 1.92) prescription at discharge.
conclusionsChanges in patient profile did not affect long-term prognosis; instead, treatment modalities accounted for the observed improvement in five-year survival.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.